Clinical proteomics identified ATP-dependent RNA helicase DDX39 as a novel biomarker to predict poor prognosis of patients with gastrointestinal stromal tumor

Journal of Proteomics

Volumn 75, Issue 4, 2012, Pages 1089-1098

  Kikuta, Kazutaka ^a,b,i   Kubota, Daisuke ^a,c   Saito, Tsuyoshi ^c   Orita, Hajime ^d   Yoshida, Akihiko ^e,f   Tsuda, Hitoshi ^e   Suehara, Yoshiyuki ^c   Katai, Hitoshi ^e   Shimada, Yasuhiro ^e   Toyama, Yoshiaki ^b   Sato, Koichi ^d   Yao, Takashi ^c   Kaneko, Kazuo ^c   Beppu, Yasuo ^e   Murakami, Yasufumi ^g,h   Kawai, Akira ^e   Kondo, Tadashi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g TOKYO UNIVERSITY OF SCIENCE   (Japan)

^h BioMatrix Research Institute   (Japan)

ⁱ Federation of National Public Service Personnel Mutual Aid Associations   (Japan)

Author keywords

2D DIGE; ATP dependent RNA helicase DDX39; Biomarker; Gastrointestinal stromal tumor; Prognosis

Indexed keywords

ADENOSINE TRIPHOSPHATE; PROTEIN TYROSINE KINASE INHIBITOR; RNA HELICASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MASS SPECTROMETRY; METASTASIS; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEOMICS; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

ADENOSINE TRIPHOSPHATE; AGED; DEAD-BOX RNA HELICASES; FEMALE; GASTROINTESTINAL STROMAL TUMORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; ISOELECTRIC POINT; MALE; MASS SPECTROMETRY; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84855886307     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2011.10.005     Document Type: Article

References (44)

1. Joensuu H., Kindblom L.G. Gastrointestinal stromal tumors-a review. Acta Orthop Scand Suppl 2004, 75:62-71.
2. Miettinen M., El-Rifai W., HLS L., Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002, 33:478-483.
3. Dematteo R.P., Owzar K., Maki R. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST). 2007. North American Intergroup Phase III trial ACOSOG Z9001. J Clin Oncol, ASCO Annual Meeting Proceedings 2007, 25:10079.
4. Heinrich M.C., Corless C.L., Blanke C.D., Demetri G.D., Joensuu H., Roberts P.J., et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006, 24:4764.
5. Debiec-Rychter M., Dumez H., Judson I., Wasag B., Verweij J., Brown M., et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004, 40:689-695.
6. Debiec-Rychter M., Sciot R., Le Cesne A., Schlemmer M., Hohenberger P., van Oosterom A.T., et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006, 42:1093-1103.
7. Schneider-Stock R., Boltze C., Lasota J., Miettinen M., Peters B., Pross M., et al. High prognostic value of p16INK4 alterations in gastrointestinal stromal tumors. J Clin Oncol 2003, 21:1688-1697.
8. Schneider-Stock R., Boltze C., Lasota J., Peters B., Corless C.L., Ruemmele P., et al. Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study. AACR 2005, 638-645.
9. Suehara Y., Kondo T., Seki K., Shibata T., Fujii K., Gotoh M., et al. Pfetin as a prognostic biomarker of gastrointestinal stromal tumors revealed by proteomics. Clin Cancer Res 2008, 14:1707-1717.
10. LA Stankey R.H. Pathology and genetics of tumours of the digestive system 2000, IARC Press, Lyon.
11. Hasegawa T., Matsuno Y., Shimoda T., Hirohashi S. Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol 2002, 33:669-676.
12. Unlu M., Morgan M.E., Minden J.S. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 1997, 18:2071-2077.
13. Yokoo H., Kondo T., Fujii K., Yamada T., Todo S., Hirohashi S. Proteomic signature corresponding to alpha fetoprotein expression in liver cancer cells. Hepatology 2004, 40:609-617.
14. Suehara Y., Kondo T., Fujii K., Hasegawa T., Kawai A., Seki K., et al. Proteomic signatures corresponding to histological classification and grading of soft-tissue sarcomas. Proteomics 2006, 6:4402-4409.
15. Kondo T., Hirohashi S. Application of highly sensitive fluorescent dyes (CyDye DIGE Fluor saturation dyes) to laser microdissection and two-dimensional difference gel electrophoresis (2D-DIGE) for cancer proteomics. Nat Protoc 2007, 1:2940-2956.
16. Kaplan E. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
17. Cox D. Regression models and life table. J R Stat Soc 1972, 34:187-220.
18. Voris B.P., Young D.A. Very-high-resolution two-dimensional gel electrophoresis of proteins using giant gels. Anal Biochem 1980, 104:478-484.
19. Campostrini N., Areces L.B., Rappsilber J., Pietrogrande M.C., Dondi F., Pastorino F., et al. Spot overlapping in two-dimensional maps: a serious problem ignored for much too long. Proteomics 2005, 5:2385-2395.
20. Alban A., David S.O., Bjorkesten L., Andersson C., Sloge E., Lewis S., et al. A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 2003, 3:36-44.
21. Kinnula V.L., Crapo J.D. Superoxide dismutases in malignant cells and human tumors. Free Radic Biol Med 2004, 36:718-744.
22. Sugiura T., Sakurai K., Nagano Y. Intracellular characterization of DDX39, a novel growth-associated RNA helicase. Exp Cell Res 2007, 313:782-790.
23. Sugiura T., Nagano Y., Noguchi Y. DDX39, upregulated in lung squamous cell cancer, displays RNA helicase activities and promotes cancer cell growth. Cancer Biol Ther 2007, 6:957-964.
24. Yoo H.H., Chung I.K. Requirement of DDX39 DEAD box RNA helicase for genome integrity and telomere protection. Aging Cell 2011, 10:557-571.
25. Dematteo R.P., Ballman K.V., Antonescu C.R., Maki R.G., Pisters P.W., Demetri G.D., et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 373:1097-1104.
26. Huang H.Y., Huang W.W., Lin C.N., Eng H.L., Li S.H., Li C.F., et al. Immunohistochemical expression of p16INK4A, Ki-67, and Mcm2 proteins in gastrointestinal stromal tumors: prognostic implications and correlations with risk stratification of NIH consensus criteria. Ann Surg Oncol 2006, 13:1633-1644.
27. Schmieder M., Wolf S., Danner B., Stoehr S., Juchems M.S., Wuerl P., et al. p16 expression differentiates high-risk gastrointestinal stromal tumor and predicts poor outcome. Neoplasia 2008, 10:1154-1162.
28. Schneider-Stock R., Boltze C., Lasota J., Peters B., Corless C.L., Ruemmele P., et al. Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study. Clin Cancer Res 2005, 11:638-645.
29. Steigen S.E., Bjerkehagen B., Haugland H.K., Nordrum I.S., Loberg E.M., Isaksen V., et al. Diagnostic and prognostic markers for gastrointestinal stromal tumors in Norway. Mod Pathol 2008, 21:46-53.
30. Gumurdulu D., Erdogan S., Kayaselcuk F., Seydaoglu G., Parsak C.K., Demircan O., et al. Expression of COX-2, PCNA, Ki-67 and p53 in gastrointestinal stromal tumors and its relationship with histopathological parameters. World J Gastroenterol 2007, 13:426-431.
31. Neves L.R., Oshima C.T., Artigiani-Neto R., Yanaguibashi G., Lourenco L.G., Forones N.M. Ki67 and p53 in gastrointestinal stromal tumors-GIST. Arq Gastroenterol 2009, 46:116-120.
32. Turkoz H.K., Alkan I., Sisman S., Ozcan D. Cyclooxygenase-2 expression and connection with tumor recurrence and histopathologic parameters in gastrointestinal stromal tumors. APMIS 2009, 117:825-830.
33. Braconi C., Bracci R., Bearzi I., Bianchi F., Sabato S., Mandolesi A., et al. Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. Ann Oncol 2008, 19:1293-1298.
34. Meara R.S., Cangiarella J., Simsir A., Horton D., Eltoum I., Chhieng D.C. Prediction of aggressiveness of gastrointestinal stromal tumours based on immunostaining with bcl-2, Ki-67 and p53. Cytopathology 2007, 18:283-289.
35. Steinert D.M., Oyarzo M., Wang X., Choi H., Thall P.F., Medeiros L.J., et al. Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate. Cancer 2006, 106:1617-1623.
36. Di Vizio D., Demichelis F., Simonetti S., Pettinato G., Terracciano L., Tornillo L., et al. Skp2 expression is associated with high risk and elevated Ki67 expression in gastrointestinal stromal tumours. BMC Cancer 2008, 8:134.
37. Liu F.Y., Qi J.P., Xu F.L., Wu A.P. Clinicopathological and immunohistochemical analysis of gastrointestinal stromal tumor. World J Gastroenterol 2006, 12:4161-4165.
38. Martinho O., Gouveia A., Silva P., Pimenta A., Reis R.M., Lopes J.M. Loss of RKIP expression is associated with poor survival in GISTs. Virchows Arch 2009, 455:277-284.
39. Hsu K.H., Tsai H.W., Shan Y.S., Lin P.W. Significance of CD44 expression in gastrointestinal stromal tumors in relation to disease progression and survival. World J Surg 2007, 31:1438-1444.
40. Montgomery E., Abraham S.C., Fisher C., Deasel M.R., Amr S.S., Sheikh S.S., et al. CD44 loss in gastric stromal tumors as a prognostic marker. Am J Surg Pathol 2004, 28:168-177.
41. Yamaguchi U., Nakayama R., Honda K., Ichikawa H., Hasegawa T., Shitashige M., et al. Distinct gene expression-defined classes of gastrointestinal stromal tumor. J Clin Oncol 2008, 26:4100-4108.
42. Kaifi J.T., Strelow A., Schurr P.G., Reichelt U., Yekebas E.F., Wachowiak R., et al. L1 (CD171) is highly expressed in gastrointestinal stromal tumors. Mod Pathol 2006, 19:399-406.
43. Kikuta K., Gotoh M., Kanda T., Tochigi N., Shimoda T., Hasegawa T., et al. Pfetin as a prognostic biomarker in gastrointestinal stromal tumor: novel monoclonal antibody and external validation study in multiple clinical facilities. Jpn J Clin Oncol 2010, 40:60-72.
44. Kubota D., Orita H., Yoshida A., Gotoh M., Kanda T., Tsuda H., et al. Pfetin as a prognostic biomarker for gastrointestinal stromal tumor: validation study in multiple clinical facilities. Jpn J Clin Oncol 2011, 41:1194-1202.